Trial reportCancer2022
A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index.
Trial report in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 43 citations in OpenAlex.
- Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study.The oncologist · 2025Trial
- Anamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2.Journal of cachexia, sarcopenia and muscle · 2025Trial
- Clinical efficacy and safety evaluation of Buzhongyiqi pills on appetite improvement in patients with colorectal cancer receiving chemotherapy: a pilot randomized cross-over clinical trial.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2024Trial
- Trial
- Machine learning for predicting muscle loss after radiotherapy using clinical and toxicity data in oral cavity cancer.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Association between postoperative iliopsoas muscle cross-sectional area changes and prognosis in elderly patients with lung cancer.JTCVS open · 2026Article
- The Patient Experience of Cancer-Related Cachexia: Implications for Patient-Reported Outcomes Measures.Clinical Medicine Insights. Oncology · 2026Article
- Mechanisms of postoperative anorexia in surgical patients: a narrative review.Frontiers in neuroscience · 2026Review
- Anamorelin Induced Hyperglycemia in a Patient with Type 1 Diabetes by Stimulating Growth Hormone Secretion.Internal medicine (Tokyo, Japan) · 2025Article
- Physical Activity, Exerkines, and Their Role in Cancer Cachexia.International journal of molecular sciences · 2025Review
- Cancer therapy and cachexia.The Journal of clinical investigation · 2025Review
- Cancer cachexia onset and survival outcomes in metastatic colorectal cancer: Comparative assessment of the asian working group for cachexia and the European palliative care research collaborative criteria, and utility of modified glasgow prognostic score.International journal of colorectal disease · 2025Article
- Effect of anamorelin treatment duration on survival of patients with cancer cachexia: A retrospective study.Molecular and clinical oncology · 2025Article
- Real-world effectiveness of anamorelin in patients with unresectable and relapse pancreatic cancer: a prospective observational study.Journal of gastrointestinal oncology · 2025Article
- Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with a Poor Performance Status.Internal medicine (Tokyo, Japan) · 2025Article
- Early administration of anamorelin improves cancer cachexia in gastrointestinal cancer patients: an observational study.Scientific reports · 2024Observational
- Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A.Journal of cachexia, sarcopenia and muscle · 2024Observational
- Comment on 'Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A' by Miura et al.Journal of cachexia, sarcopenia and muscle · 2024Article
- Anamorelin for the Treatment of Cancer Anorexia-Cachexia Syndrome.Current oncology reports · 2024Review
- Real-world safety and effectiveness of anamorelin for cancer cachexia: Interim analysis of post-marketing surveillance in Japan.Cancer medicine · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 13 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer cachexia is a syndrome characterized by anorexia and decreased body weight. This study evaluated the efficacy and safety of anamorelin, an orally active, selective ghrelin receptor agonist, in patients with cancer cachexia and a low body mass index (BMI).
methodsThis multicenter, open-label, single-arm study enrolled Japanese patients with non-small cell lung cancer or gastrointestinal cancer with cancer cachexia (BMI < 20 kg/m
resultsOne hundred two patients were eligible and enrolled. The means and standard deviations for age and BMI were 71.0 ± 8.2 years and 17.47 ± 1.48 kg/m
conclusionsAnamorelin improved body weight and anorexia-related symptoms in patients with cancer cachexia and a low BMI with durable efficacy and favorable safety and tolerability. LAY SUMMARY: Anamorelin is a drug that stimulates appetite and promotes weight gain. This clinical trial was aimed at determining its efficacy and safety in Japanese cancer patients with a low body mass index and cachexia, a syndrome associated with anorexia and weight loss. Anamorelin was found to improve body weight and anorexia-related symptoms in these patients, and these effects were durable for up to 24 weeks. Moreover, anamorelin was generally well tolerated. These findings suggest that anamorelin is a valuable treatment option for patients with cancer cachexia and a low body mass index.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.